PMID- 27076167
OWN - NLM
STAT- MEDLINE
DCOM- 20161221
LR  - 20161230
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1403
DP  - 2016
TI  - T-Cell Epitope Discovery for Therapeutic Cancer Vaccines.
PG  - 779-96
LID - 10.1007/978-1-4939-3387-7_45 [doi]
AB  - The success of recent immune checkpoint blockade trials in solid tumors has 
      demonstrated the tremendous potential of immune-mediated treatment strategies for 
      cancer therapy. These immune therapies activate preexisting cytotoxic CD8(+) T 
      cells (CTL) to selectively target and eradicate malignant cells. In vitro models 
      suggest that these therapies may be more effective in combination with priming of 
      CTL using cancer vaccines. CTL-mediated tumor targeting is achieved by its 
      recognition of tumor antigenic epitopes presented on human leukocyte antigen 
      (HLA) class I molecules by tumor cells. Discovering CTL-antigenic epitopes is 
      therefore central to the design of therapeutic T-cell vaccines and immune 
      monitoring of these complex immunotherapies. However, selecting and monitoring 
      T-cell epitopes remains difficult due to the extensive polymorphism of HLA 
      alleles and the presence of confounding non-immunogenic self-peptides. To 
      overcome these challenges, this chapter presents methodologies for the design of 
      CTL-targeted vaccines using selection of target HLA alleles, novel integrated 
      computational strategies to predict HLA-class I CTL epitopes, and epitope 
      validation methods using short-term ex vivo T-cell stimulation. This strategy 
      results in the improved efficiency for selecting antigenic epitopes for 
      CTL-mediated vaccines and for immune monitoring of tumor antigens.
FAU - Krishna, Sri
AU  - Krishna S
AD  - Center for Personalized Diagnostics, The Biodesign Institute, Arizona State 
      University, Tempe, AZ, 85287, USA.
AD  - School of Biological and Health Systems Engineering, Arizona State University, 
      Tempe, AZ, 85287, USA.
FAU - Anderson, Karen S
AU  - Anderson KS
AD  - Center for Personalized Diagnostics, The Biodesign Institute, Arizona State 
      University, Tempe, AZ, 85287, USA. Karen.Anderson.1@asu.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Alleles
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cancer Vaccines/*immunology
MH  - Computational Biology/*methods
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - HLA Antigens/genetics/immunology
MH  - Humans
OTO - NOTNLM
OT  - Cytotoxic CD8+ T cells
OT  - HLA typing
OT  - T-cell epitope
EDAT- 2016/04/15 06:00
MHDA- 2016/12/22 06:00
CRDT- 2016/04/15 06:00
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2016/12/22 06:00 [medline]
AID - 10.1007/978-1-4939-3387-7_45 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2016;1403:779-96. doi: 10.1007/978-1-4939-3387-7_45.